DIM
ADCT icon

DLK Investment Management’s ADC Therapeutics ADCT Stock Holding History

DLK Investment Management’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$105K Buy
33,155
+7,850
+31% +$22.9K 0.04% 80
2026
Q1 		$94.9K Hold
25,305
– – 0.04% 82
2025
Q4 		$89.3K Hold
25,305
– – 0.03% 81
2025
Q3 		$101K Hold
25,305
– – 0.04% 79
2025
Q2 		$67.8K Sell
25,305
-1,500
-6% -$3.15K 0.03% 77
2025
Q1 		$37.8K Buy
26,805
+1,000
+4% +$1.7K 0.02% 77
2024
Q4 		$51.4K Sell
25,805
-7,350
-22% -$19.2K 0.02% 78
2024
Q3 		$104K Hold
33,155
– – 0.04% 89
2024
Q2 		$105K Hold
33,155
– – 0.04% 83
2024
Q1 		$149K Hold
33,155
– – 0.06% 79
2023
Q4 		$55K Buy
+33,155
New +$30.6K 0.03% 86

Other funds holding ADCT

RWP
Revolve Wealth Partners Hackensack, New Jersey $965M AUM 22.88% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
SOADOR
State of Alaska Department of Revenue Juneau, Alaska $10.1B AUM 42.83% 1-Year Est. Return
SCM
Saxony Capital Management St. Louis, Missouri $218M AUM 24.57% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
EWA
EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.74% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

DLK Investment Management's ADCT Position: Q2 2026 in Review

DLK Investment Management increased its ADC Therapeutics (ADCT) stake by 31% in Q2 2026, buying an estimated $22.9K and bringing the position to 33,155 shares worth $105K. The position accounts for 0.04% of the portfolio, ranked #80.

DLK Investment Management first reported a position in ADCT in Q4 2023 and has held it in 11 quarters since. The position peaked at $149K in Q1 2024. 12 funds tracked by Wall St. Rank hold ADCT as of Q2 2026.

  • DLK Investment Management held 33,155 shares of ADC Therapeutics worth $105K as of Q2 2026.
  • DLK Investment Management bought 7,850 ADC Therapeutics shares in Q2 2026, an estimated $22.9K.
  • ADC Therapeutics made up 0.04% of DLK Investment Management's portfolio in Q2 2026, its #80 holding.
  • DLK Investment Management first reported a position in ADC Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • DLK Investment Management's ADC Therapeutics position peaked at $149K in Q1 2024.
  • 12 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2026.

Based on DLK Investment Management's 13F filing for Q2 2026, filed 14 Jul 2026.